Jupiter Asset Management Ltd. Increases Stock Position in Aurinia Pharmaceuticals Inc $AUPH

Jupiter Asset Management Ltd. increased its position in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) by 9.2% during the 4th quarter, Holdings Channel reports. The firm owned 899,483 shares of the biotechnology company’s stock after purchasing an additional 75,904 shares during the quarter. Jupiter Asset Management Ltd.’s holdings in Aurinia Pharmaceuticals were worth $14,347,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership lifted its position in shares of Aurinia Pharmaceuticals by 213.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 3,374,021 shares of the biotechnology company’s stock worth $37,283,000 after buying an additional 2,297,903 shares in the last quarter. Marshall Wace LLP increased its position in shares of Aurinia Pharmaceuticals by 1,272.5% during the third quarter. Marshall Wace LLP now owns 1,483,132 shares of the biotechnology company’s stock valued at $16,389,000 after acquiring an additional 1,375,072 shares during the last quarter. Two Sigma Investments LP increased its position in shares of Aurinia Pharmaceuticals by 728.6% during the third quarter. Two Sigma Investments LP now owns 1,341,067 shares of the biotechnology company’s stock valued at $14,819,000 after acquiring an additional 1,179,219 shares during the last quarter. LSV Asset Management bought a new stake in Aurinia Pharmaceuticals during the fourth quarter worth $10,477,000. Finally, Jacobs Levy Equity Management Inc. lifted its holdings in Aurinia Pharmaceuticals by 63.0% during the third quarter. Jacobs Levy Equity Management Inc. now owns 1,219,451 shares of the biotechnology company’s stock worth $13,475,000 after acquiring an additional 471,338 shares during the period. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Stock Down 0.1%

Aurinia Pharmaceuticals stock opened at $15.33 on Friday. The firm has a 50 day moving average price of $15.49 and a 200-day moving average price of $15.25. The company has a quick ratio of 5.01, a current ratio of 5.55 and a debt-to-equity ratio of 0.08. Aurinia Pharmaceuticals Inc has a twelve month low of $7.28 and a twelve month high of $16.88. The company has a market capitalization of $1.97 billion, a P/E ratio of 7.06 and a beta of 1.44.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of $0.18 by $0.07. Aurinia Pharmaceuticals had a net margin of 99.97% and a return on equity of 26.62%. The company had revenue of $77.71 million for the quarter, compared to analysts’ expectations of $76.98 million. As a group, equities analysts predict that Aurinia Pharmaceuticals Inc will post 0.82 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded Aurinia Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, May 15th. Two research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Aurinia Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $17.25.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a clinical?stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.